Document:

ASSET
PURCHASE AGREEMENT

 

THIS
ASSET PURCHASE AGREEMENT (this “Agreement”) dated as of the last date provided on the signature page (the “Effective
Date”), is entered into between IMPRIMIS PHARMACEUTICALS, INC., a Delaware corporation (“Imprimis”), with a
place of business at 12264 El Camino Real, Suite 350, San Diego, California 92130, and MELT
Pharmaceuticals, Inc., a Nevada corporation (“Melt”), with a place of business at 12264 El Camino Real, Suite
350, San Diego, California 92130. The parties hereby agree as follows:

 

1.
Definitions. For the purposes of this
Agreement, the following terms shall have the respective meanings set forth below, and grammatical variations of such terms shall
have corresponding meanings:

 

1.1
“Affiliate” means, with respect to any Person, any other Person which directly or indirectly controls, is controlled
by, or is under common control with, such Person. A Person shall be regarded as in control of another Person if it owns, or directly
or indirectly controls, more than fifty percent (50%) of the voting stock or other ownership interest of the other Person, or
if it directly or indirectly possesses the power to direct or cause the direction of the management and policies of the other
Person by any means whatsoever. Notwithstanding the foregoing, for purposes of this Agreement, neither Imprimis nor Melt shall
be Affiliates of the other or the other’s Affiliates.

 

1.2
“Assets” means, collectively, (a) all Technology as of the Effective Date, (b) the Assigned Patent Rights,
(c) the Assigned Know-How Rights, and (d) all compositions, formulations, samples, data and information specific to the Technology
owned by Imprimis as of the Effective Date.

 

1.3
“Assigned Know-How Rights” means all trade secret and other know-how rights specific to the Technology owned
by Imprimis as of the Effective Date.

 

1.4
“Assigned Patent Rights” means, collectively, (a) all patents and patent applications (including provisional
patent applications) listed on Schedule A, together with all divisionals, continuations and continuations-in-part that claim priority
to, or common priority with, the foregoing; (b) all patents issuing therefrom (including utility models and design patents and
certificates of invention); (c) all reissues, reexaminations, inter partes reviews, renewals, restorations, extensions and supplementary
protection certificates of any of the foregoing patent applications or patents; (d) all confirmation patents, registration patents
or patents of addition based on any of the foregoing patents; and (e) all foreign counterparts of any of the foregoing, or as
applicable portions thereof.

 

1.5
“Confidential Information” means all information and data that (a) is provided by one party to the other party
under this Agreement, and (b) if disclosed in writing or other tangible medium is marked or identified as confidential at the
time of disclosure to the recipient, is acknowledged at the time of disclosure to be confidential, or otherwise should reasonably
be deemed to be confidential. Melt’s Confidential Information includes the Assets. Notwithstanding the foregoing, Confidential
Information of a party shall not include that portion of such information and data which, and only to the extent, the recipient
can establish by written documentation: (i) is known to the recipient as evidenced by its written records before receipt thereof
from the disclosing party, (ii) is disclosed to the recipient free of confidentiality obligations by a third person who has the
right to make such disclosure, (iii) is or becomes part of the public domain through no fault of the recipient, or (iv) the recipient
can reasonably establish is independently developed by persons on behalf of recipient without access to or use of the information
disclosed by the disclosing party.

 

    	 	1	 

     

    

 

1.6
“First Commercial Sale” means, with respect to any Product, the first sale of such Product after all applicable
marketing and pricing approvals (if any) have been granted by the applicable governing health authority.

 

1.7
“GAAP” means generally accepted accounting principles in the United States of America.

 

1.8
“Imprimis Field” shall mean drug products compounded or manufactured in compounding pharmacies or outsourcing
facilities as defined and described in the Federal Food, Drug & Cosmetic Act (21 U.S.C §353a and 21 U.S.C. §353b).

 

1.9
“Licensee” means a Third Party to whom Melt or its Affiliate has granted a license, immunity or other right
under the Assigned Patent Rights to offer to sell, sell or otherwise commercialize one or more Products, provided such license
has not expired or been terminated.

 

1.10
“Melt Field” means all fields of use other than the Imprimis Field.

 

1.11
“Net Licensing Revenues” means, with respect to any Product, the aggregate consideration received by Melt or
its Affiliates in connection with the grant by Melt or its Affiliates to a Licensee of a license, immunity or other right under
the Assigned Patent Rights to offer to sell, sell or otherwise commercialize such Product, excluding amounts calculated on the
sales price of such Product.

 

1.12
“Net Receipts” means, with respect to any Product, the aggregate of the Net Sales thereof and Net Licensing
Revenues therefrom.

 

1.13
“Net Sales” means, with respect to any Product, the gross sales price for such Product invoiced by Melt, its
Licensees, or its or their respective Affiliates to customers who are not Affiliates (or are Affiliates but are the end users
of such Product) less: (a) commercially reasonable credits, allowances, discounts and rebates to, and chargebacks from the account
of, such customers; (b) freight and insurance costs in transporting such Product paid by Melt, its Licensees, or its or their
respective Affiliates and not reimbursed by such customers; (c) commercially reasonable cash, quantity and trade discounts, rebates
and other price reductions for such Product; (d) sales, use, value-added and other direct taxes assessed or imposed on the sale
or license of such Product and paid by Melt, its Licensees, or its or their respective Affiliates and not reimbursed by such customers;
(e) customs duties, tariffs, surcharges and other governmental charges incurred in exporting or importing such Product paid by
Melt, its Licensees, or its or their respective Affiliates and not reimbursed by customers; and (f) an allowance for uncollectible
or bad debts determined in accordance with GAAP. If Melt, its Licensees, or its or their respective Affiliates sell or license
any Product to an Affiliate end user at a price that reflects a credit, allowance, discount or rebate that is greater than the
same offered to otherwise similarly situated customers, the amount of the credit, allowance, discount or rebate shall not be subtracted
from the gross sales price. Net Sales shall not include the gross sales price of such Product invoiced as the result of prescriptions
written for the Product or purchases made of the Product by the investors in OHSO or by Affiliates of investors in OHSO.

 

    	 	2	 

     

    

 

1.14
“OHSO” means OHSO, LLC.

 

1.15
“Payment Period” means, on a Product-by-Product and country-by-country basis, the period of time equal to the
longer of (a) beginning on the date of the First Commercial Sale of such Product in such country and continuing during the term
for which a Valid Claim (if such Valid Claim were in an issued patent) in such country remains in effect and would be infringed
(if such Valid Claim were in an issued patent not owned by or licensed to Melt) by the manufacture, use, offer for sale, sale
or import of such Product in such country; and (b) twenty (20) years following the date of the First Commercial Sale of such Product
in such country.

 

1.16
“Person” means any individual, partnership, firm, corporation, association, trust, unincorporated organization
or other entity, as well as any syndicate or group of any of the foregoing.

 

1.17
“Product” means any product in any form or formulation that if made, used, offered for sale, sold or imported
would infringe a Valid Claim (if such Valid Claim were in an issued patent not owned by or licensed to Melt), or that otherwise
uses or incorporates the Assigned Know-How Rights.

 

1.18
“Product Supported Patent Rights” means, collectively, (a) all patent applications hereafter filed anywhere
in the world, together with all divisionals, continuations and continuations-in-part that claim priority to, or common priority
with, the foregoing; (b) all patents issuing therefrom (including utility models and design patents and certificates of invention);
(c) all reissues, reexaminations, inter partes reviews, renewals, restorations, extensions and supplementary protection certificates
of any of the foregoing patent applications or patents; (d) all confirmation patents, registration patents or patents of addition
based on any of the foregoing patents; and (e) all foreign counterparts of any of the foregoing, or as applicable portions thereof;
in each case that use or are supported by data or information derived from the development, manufacture or use of a Product or
otherwise from the exploitation of the Assets; provided, however, that Product Supported Patent Rights shall exclude the Assigned
Patent Rights.

 

1.19
“Technology” means, (a) any product in any form or formulation comprising any one or more pharmaceutical compositions
comprising versed and ketamine; and (b) all methods of manufacture and use of the foregoing.

 

1.20
“Third Party” means any Person other than Imprimis, Melt or their respective Affiliates.

 

1.21
“Valid Claim” means either (a) a claim of an issued and unexpired patent included within the Assigned Patent
Rights, which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency
of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be
invalid or unenforceable through reissue or disclaimer or otherwise, or (b) a claim of a pending patent application included within
the Assigned Patent Rights, which claim was filed in good faith and has not been abandoned or finally disallowed without the possibility
of appeal or refiling of such application.

 

    	 	3	 

     

    

 

2.
Purchase and Sale of the Assets.

 

2.1
Assets. Subject to the terms and conditions of this Agreement, Melt hereby purchases from Imprimis, and Imprimis hereby
sells, conveys, transfers and assigns to Melt, on the Effective Date, all of Imprimis’ right, title and interest in and
to the Assets. To the extent necessary to comply with applicable privacy laws, Imprimis shall have the right to redact patient
identifying information from any data or information transferred to Melt.

 

2.2
No Assumption of Liabilities. Melt shall not be obligated to assume or perform and is not assuming or performing any liabilities
or obligations of Imprimis which relate to Imprimis’ ownership of the Assets prior to the Effective Date or otherwise, whether
known or unknown, fixed or contingent, certain or uncertain, and regardless of when they are or were asserted, and Imprimis shall
remain responsible for such liabilities.

 

2.3
Transfer Documents. The sale, conveyance, transfer and assignment of the Assets may be further evidenced by the due execution
and delivery by the parties of any additional bills of sale, assignment or other title transfer documents and instruments as reasonably
requested by Melt evidencing the sale, conveyance, transfer and assignment of the Assets in accordance with this Agreement.

 

3.
License Grants.

 

3.1
Grantback License.

 

3.1.1
Subject to the terms and conditions of this Agreement, Melt hereby grants to Imprimis an exclusive (including with respect to
Melt), irrevocable, perpetual, fully paid-up, royalty-free, non-transferable (except in connection with a permitted assignment
of this Agreement), worldwide license under the Assigned Patent Rights, the Product Supported Patent Rights, and the Assigned
Know-How Rights for all purposes in the Imprimis Field.

 

3.1.2
Imprimis shall have the right to grant sublicenses, through multiple tiers, to Third Parties and Affiliates.

 

3.2
No Implied Licenses. Only licenses and rights expressly granted herein shall be of legal force and effect. No license or
other right shall be created hereunder by implication, estoppel, or otherwise.

 

    	 	4	 

     

    

 

4.
Representations and Warranties.

 

4.1
Mutual Representations and Warranties. Each party represents and warrants to the other party as follows:

 

4.1.1
Organization. Such party is duly organized, validly existing and in good standing under the laws of the jurisdiction in
which it is organized.

 

4.1.2
Authorization and Enforcement of Obligations. Such party (a) has the requisite power and authority and the legal right
to enter into this Agreement and to perform its obligations hereunder; and (b) has taken all requisite action on its part to authorize
the execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has been duly executed
and delivered on behalf of such party, and constitutes a legal, valid, binding obligation, enforceable against such party in accordance
with its terms.

 

4.1.3
Consents. All necessary consents, approvals and authorizations of all governmental authorities and other persons or entities
required to be obtained by such party in connection with this Agreement have been obtained.

 

4.1.4
No Conflict. The execution and delivery of this Agreement and the performance of such party’s obligations hereunder
(a) do not conflict with or violate any requirement of applicable laws, regulations or orders of governmental bodies; and (b)
do not conflict with, or constitute a default under, any contractual obligation of such party.

 

4.2
Disclaimer of Warranties. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN SECTION
4.1, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, REGARDING THE ASSETS OR ANY OTHER MATTER, INCLUDING
WITHOUT LIMITATION, ANY REPRESENTATION OR WARRANTY REGARDING VALIDITY, ENFORCEABILITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE OR NONINFRINGEMENT. THE ASSETS ARE PROVIDED “AS IS.”

 

5.
Financial Terms.

 

5.1
OHSO Payments. Subsequent to the entering into this Agreement, Melt may enter into a separate written agreement with OHSO,
pursuant to which Melt shall pay certain amounts to OHSO on terms and conditions to be mutually agreed by Melt and OHSO.

 

5.2
Net Receipts Payments.

 

5.2.1
Net Receipts Payment Amounts.

 

(a)
Payment Amount. Subject to the provisions in this Section 5.2.1, on a Product-by-Product and country-by-country basis,
Melt shall pay to Imprimis, on a quarterly basis, eight percent (8%) of Net Receipts during the applicable Payment Period (the
“Payment Amount”); provided, however, if, the manufacture, use, offer for sale, sale, or import of such Product
in a particular country would not infringe a Valid Claim (if such Valid Claim were in an issued patent and not owned by or licensed
to Melt), then the applicable Payment Amount with respect to such Product in such country shall be reduced by one-half (1⁄2).

 

(b)
OHSO Payments. If Melt, its Licensees, or its or their respective Affiliates is required to pay any fees or charges to
OHSO in order to make, have made, use, sell, offer to sale or import any Product, then Melt shall have the right to credit such
amounts against the Payment Amount owing to Imprimis under Section 5.2.1(a) with respect to sales of such Product; provided,
however, that Melt shall not reduce the Payment Amount with respect to sales of such Product for any period to less than (i) five
percent (5%) of Net Receipts of such Product for such period if the manufacture, use, offer for sale, sale, or import of such
Product in a particular country would infringe a Valid Claim (if such Valid Claim were in an issued patent and not owned by or
licensed to Melt), or (ii) two and one-half percent (21⁄2%) of Net Receipts of such Product for such period if the manufacture,
use, offer for sale, sale, or import of such Product in a particular country would not infringe a Valid Claim (if such Valid Claim
were in an issued patent and not owned by or licensed to Melt).

 

    	 	5	 

     

    

 

(c)
Third Party Royalties. If Melt, its Licensees or its or their respective Affiliates is required to pay royalties to any
Third Party (other than OHSO) in order to make, have made, use, sell, offer to sale or import any Product, then Melt shall have
the right to credit fifty percent (50%) of such Third Party royalty payments against the Payment Amount owing to Imprimis under
Section 5.2.1(a) with respect to sales of such Product; provided, however, that Melt shall not reduce the Payment Amount
with respect to sales of such Product for any period to less than (i) five percent (5%) of Net Receipts of such Product for such
period if the manufacture, use, offer for sale, sale, or import of such Product in a particular country would infringe a Valid
Claim (if such Valid Claim were in an issued patent and not owned by or licensed to Melt), or (ii) two and one-half percent (21⁄2%)
of Net Receipts of such Product for such period if the manufacture, use, offer for sale, sale, or import of such Product in a
particular country would not infringe a Valid Claim (if such Valid Claim were in an issued patent and not owned by or licensed
to Melt).

 

(d)
Combination/Bundled Products. In the event that a Product is sold by Melt, its Licensees or its or their respective Affiliates
in combination with one or more products which is itself not a Product at a single price, then Net Sales shall be calculated by
multiplying the sales price of such combination sale by the fraction A/(A+B) where A is the fair market value of the Product(s)
and B is the fair market value of the other product(s) in the combination sale, each as reasonably determined by mutual written
agreement of the parties.

 

5.2.2
Reports and Net Receipts Payments. Within sixty (60) days after the end of each calendar quarter during the applicable
Payment Period, Melt shall deliver to Imprimis a report setting forth for such calendar quarter (a) the calculation of the applicable
Payment Amount, including without limitation the Net Licensing Revenues and Net Sales of each Product; (b) the payments due under
this Agreement for the sale of each Product; and (c) the applicable exchange rate as determined below. Melt shall remit the total
payments due for the sale or license of Products during such calendar quarter at the time such report is made. No such reports
or payments will be due for any Product before the First Commercial Sale of such Product. With respect to Net Receipts received
in United States dollars, all amounts shall be expressed in United States dollars. With respect to Net Receipts received in a
currency other than United States dollars, all amounts shall be expressed both in the currency in which the amount is invoiced
(or received as applicable) and in the United States dollar equivalent. The United States dollar equivalent shall be calculated
using the average of the exchange rate (local currency per US$1) published in The Wall Street Journal, Western Edition,
under the heading “Currency Trading” on the last business day of each month during the applicable calendar quarter.

 

    	 	6	 

     

    

 

5.3
Payment Provisions.

 

5.3.1
Payment Method. All payments by Melt to Imprimis hereunder shall be in United States dollars in immediately available funds
and shall be made by wire transfer from a United States bank located in the United States to such bank account as designated from
time to time by Imprimis to Melt.

 

5.3.2
Payment Terms. The Payment Amount shown to have accrued by each report provided for under Section 5.2.2 shall be due on
the date such report is due. Payment of Payment Amount in whole or in part may be made in advance of such due date. Late payments
shall incur interest at the rate of one percent (1%) per month from the date such payments were originally due.

 

5.3.3
Withholding Taxes. Melt shall be entitled to deduct the amount of any withholding taxes, value-added taxes or other taxes,
levies or charges with respect to such amounts, other than United States taxes, payable by Melt, its Licensees, or its or their
respective Affiliates, or any taxes required to be withheld by Melt, its Licensees, or its or their respective Affiliates, to
the extent Melt, its Licensees, or its or their respective Affiliates pay to the appropriate governmental authority on behalf
of Imprimis such taxes, levies or charges. Melt shall use reasonable efforts to minimize any such taxes, levies or charges required
to be withheld on behalf of Imprimis by Melt, its Licensees, or its or their respective Affiliates. Melt promptly shall deliver
to Imprimis proof of payment of all such taxes, levies and other charges, together with copies of all communications from or with
such governmental authority with respect thereto.

 

5.4
Audits. Upon the written request of Imprimis and not more than once in each calendar year, Melt shall permit an independent
certified public accounting firm selected by Imprimis and reasonably acceptable to Melt, at Imprimis’ expense, to have access
during normal business hours to such of the financial records of Imprimis as may be reasonably necessary to verify the accuracy
of the Payment Amount reports hereunder for the eight (8) calendar quarters immediately prior to the date of such request. If
such accounting firm concludes that additional amounts were owed during the audited period, Melt shall pay such additional amounts
within thirty (30) days after the date Imprimis delivers to Melt such accounting firm’s written report so concluding. The
fees charged by such accounting firm shall be paid by Imprimis; provided, however, if the audit discloses that the Payment Amount
payable by Melt for such period are more than one hundred ten percent (110%) of the Payment Amount actually paid for such period,
then Melt shall pay the fees and expenses charged by such accounting firm. Imprimis shall cause its accounting firm to retain
all financial information subject to review under this Section 5.4 in strict confidence. Imprimis shall treat all such financial
information as Melt’s confidential information, and shall not disclose such financial information to any Third Party or
use it for any purpose other than as specified in this Section 5.4.

 

    	 	7	 

     

    

 

6.
Post-Effective Date Covenants.

 

6.1
Melt Diligence.

 

6.1.1
Melt shall use commercially reasonable efforts (whether alone or with or through its Licensees or its or their respective Affiliates)
to research, develop and commercialize Products.

 

6.1.2
Melt shall control, at its sole expense, the preparation, filing, prosecution, maintenance and enforcement of the Assigned Patent
Rights consistent with prudent business practices, and shall consider in good faith the interests of Imprimis and OHSO.

 

6.2
Imprimis Covenants.

 

6.2.1
Within thirty (30) days after the Effective Date, Imprimis shall transfer to Melt all tangible embodiments of the Technology in
the possession and control of Imprimis.

 

6.2.2
Imprimis shall provide cooperation reasonably requested by Melt in connection with Melt’s efforts to establish, perfect,
defend, or enforce its rights in or to the Assets (including without limitation the Assigned Patent Rights). Such cooperation
shall include, without limitation, (a) executing such further assignments, transfers, licenses, releases and consents, and (b)
providing such data and information, consulting with Melt and executing and delivering all such further documents and instruments,
in each case as reasonably requested by Melt regarding the Assets (including without limitation the Assigned Patent Rights).

 

6.2.3
If a New Drug Application for a Product is filed by or on behalf of Melt, then, commencing thirty (30) days after receipt by Imprimis
of Melt’s express written request, Imprimis shall cease compounding pharmaceutical products in a solid dosage form for sublingually-delivered
conscious sedation that contain the same active ingredient as contained in such Product (or if there is more than one active ingredient
contained in such Product, then the same combination of active ingredients as is contained in such Product) in the Melt Field
until such time as Melt, its Licensees and its or their respective Affiliates (or their successors) cease for at least twelve
(12) months bona fide development or commercialization of such Product. Melt promptly shall notify Imprimis in writing of any
such cessation.

 

7.
Indemnification.

 

7.1
Indemnification of Melt. Subject to the provisions of this Section 7, Imprimis shall indemnify, defend and hold harmless
Melt, its officers, directors, affiliates, agents, stockholders and representatives (collectively, the “Melt Indemnitees”),
from and against any and all losses, liabilities, damages and expenses (including without limitation reasonable attorneys’
fees and costs) incurred as a result of any claim, demand, action or proceeding by any Third Party (collectively, “Losses”)
incurred or suffered by an Melt Indemnitee to the extent arising out of:

 

7.1.1
any breach of the representations and warranties of Imprimis set forth in this Agreement;

 

    	 	8	 

     

    

 

7.1.2
any breach of any covenant or agreement of Imprimis set forth in this Agreement or in any certificate, instrument, or other document
delivered pursuant to this Agreement; and

 

7.1.3
the ownership or exploitation of the Assets prior to the Effective Date.

 

7.2
Indemnification of Imprimis. Subject to the provisions of this Section 7, Melt shall indemnify and hold harmless Imprimis,
its officers, directors, affiliates, agents, stockholders and representatives (collectively, the “Imprimis Indemnitees”),
from and against any and all Losses incurred or suffered by an Imprimis Indemnitee to the extent arising out of:

 

7.2.1
any breach of the representations and warranties of Melt set forth in this Agreement;

 

7.2.2
any breach of any covenant or agreement of Melt set forth in this Agreement or in any certificate, instrument, or other document
delivered pursuant to this Agreement;

 

7.2.3
the ownership or exploitation of the Assets after the Effective Date or the manufacture, use, sale or other exploitation of any
Product solely by Melt, its Licensees or their respective Affiliates or the use of any Product by their customers.

 

7.3
Procedure. A party seeking indemnification (the “Indemnitee”) shall promptly notify the other party
(the “Indemnifying Party”) in writing of a claim or suit; provided that an Indemnitee’s failure to give
such notice or delay in giving such notice shall not affect such Indemnitee’s right to indemnification under this Section
7 except to the extent that the Indemnifying Party has been prejudiced by such failure or delay. The Indemnifying Party shall
have the right to control the defense of all indemnification claims hereunder. The Indemnitee shall have the right to participate
at its own expense in the claim or suit with counsel of its own choosing. The Indemnifying Party shall consult with the Indemnitee
in good faith with respect to all non-privileged aspects of the defense strategy. The Indemnitee shall cooperate with the Indemnifying
Party as reasonably requested, at the Indemnifying Party’s sole cost and expense. The Indemnifying Party shall not settle
any claim or suit without the Indemnitee’s prior written consent, which consent shall not be unreasonably withheld.

 

8.
Confidentiality.

 

8.1
Confidential Information. During the term of this Agreement, and for a period of five (5) years following the expiration
or earlier termination hereof, except as otherwise provided in this Section 8, each party shall maintain in confidence the Confidential
Information of the other party except as expressly permitted herein, and shall not use, disclose or grant the use of the Confidential
Information except on a need-to-know basis to those directors, officers, employees, (sub)licensees and contractors, to the extent
such disclosure is reasonably necessary in connection with performing its obligations or exercising its rights under this Agreement.
To the extent that disclosure by a party is authorized by this Agreement, prior to disclosure, such party shall obtain agreement
of any such Person to hold in confidence and not make use of the Confidential Information for any purpose other than those permitted
by this Agreement.

 

    	 	9	 

     

    

 

8.2
Terms of this Agreement. Neither party shall disclose any terms or conditions of this Agreement to any Third Party without
the prior consent of the other party; provided, however, that a party may disclose the terms or conditions of this Agreement,
(a) on a need-to-know basis to its legal and financial advisors to the extent such disclosure is reasonably necessary, and (b)
to a Third Party in confidence in connection with (i) an equity investment in such party, (ii) a merger, consolidation or similar
transaction by such party, (iii) a permitted (sub)license under this Agreement, or (iv) the sale of all or substantially all of
the assets of such party. Notwithstanding the foregoing, prior to execution of this Agreement, the parties have agreed upon the
substance of information that can be used to describe the terms of this transaction, and each party may disclose such information,
as modified by mutual agreement from time to time, without the other party’s consent.

 

8.3
Permitted Disclosures. The confidentiality obligations contained in this Section 8 shall not apply to the extent that a
party is required (a) in the reasonable opinion of such party’s legal counsel, to disclose information by applicable law,
regulation, rule (including rule of a stock exchange or automated quotation system), order of a governmental agency or a court
of competent jurisdiction or legal process, including tax authorities, or (b) to disclose information to any governmental agency
for purposes of obtaining approval to test or market a product, provided in either case that, to the extent practicable, such
party shall provide written notice thereof to the other party and sufficient opportunity to object to any such disclosure or to
request confidential treatment. Notwithstanding anything to the contrary herein, either party may disclose the terms and conditions
of this Agreement to any Person with whom such party has, or is proposing to enter into, a business relationship, as long as such
Person has entered into a confidentiality agreement with such party.

 

8.4
Injunctive Relief. Each party acknowledges that it will be impossible to measure in money the damage to the other party
if such party fails to comply with the obligations imposed by this Section 8, and that, in the event of any such failure, the
other party may not have an adequate remedy at law or in damages. Accordingly, each party agrees that injunctive relief or other
equitable remedy, in addition to remedies at law or damages, is an appropriate remedy for any such failure and shall not oppose
the granting of such relief on the basis that the disclosing party has an adequate remedy at law. Each party agrees that it shall
not seek, and agrees to waive any requirement for, the securing or posting of a bond in connection with the other party seeking
or obtaining such equitable relief.

 

9.
Term and Termination.

 

9.1
Term. The term of this Agreement shall continue until expiration of all payment obligations hereunder, unless earlier terminated
as set forth below.

 

9.2
Termination.

 

9.2.1
If Melt, its Licensee, or their respective Affiliates fails either to file an Investigational New Drug Application in the United
States for a Product, or to generate Net Receipts, before June 19, 2022, then (unless the parties otherwise mutually agree in
writing) Imprimis shall have the right, at its option and as its sole remedy, to terminate the Agreement.

 

    	 	10	 

     

    

 

9.2.2
In the event of the termination of this Agreement in accordance with this Section 9.2, Melt shall re-assign the Technology
and the other Assets to Imprimis or its designee. Melt shall execute, acknowledge and deliver such further documents and instruments
and perform all such other acts as may be reasonably necessary or appropriate in order to effectuate the foregoing.

 

9.3
Survival. Expiration or termination of this Agreement shall be without prejudice to any rights which shall have accrued
to the benefit of any party prior to such expiration or termination. Without limiting the foregoing, Sections 3, 4.2, 5, 7, 8,
9.2.2, 9.3 and 10 shall survive any expiration or termination of this Agreement.

 

10.
Miscellaneous.

 

10.1
Further Actions. Each party shall execute, acknowledge and deliver such further documents and instruments and to perform
all such other acts as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

 

10.2
LIMITATION OF LIABILITY. IN NO EVENT SHALL A PARTY BE LIABLE FOR SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT
OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS
AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. NOTHING IN THIS SECTION 10.2 SHALL LIMIT OR RESTRICT THE RIGHTS OR LIABILITIES
OF EITHER PARTY UNDER SECTIONS 7 AND 8.

 

10.3
Residuals. Notwithstanding anything to the contrary in this Agreement, Imprimis shall have the right to use any general
knowledge, skills and experience and any information retained in the unaided memory of an individual employed or otherwise engaged
by Imprimis.

 

10.4
Assignment. Neither party shall assign its rights or obligations under this Agreement without the prior written consent
of the other party; provided, however, that a party may, without such consent, assign this Agreement and its rights and obligations
hereunder (a) to any Affiliate, or (b) in connection with the transfer or sale of all or substantially all of its business to
which this Agreement relates, or in the event of its merger, consolidation, change in control or similar transaction. Any permitted
assignee shall assume all obligations of its assignor under this Agreement. Any purported assignment in violation of this Section
10.4 shall be void.

 

10.5
Severability. Any provision of this Agreement which is illegal, invalid or unenforceable shall be ineffective to the extent
of such illegality, invalidity or unenforceability, without affecting in any way the remaining provisions hereof.

 

10.6
Governing Law; Exclusive Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws of
the State of California, without regard to the conflicts of law principles thereof. Each of the parties hereto irrevocably consents
to the exclusive jurisdiction and venue of any federal court located in the Southern District of the State of California or state
court in San Diego, California having jurisdiction, in connection with any matter based upon or arising out of this Agreement
or the matters contemplated herein, agrees that process may be served upon them in any manner authorized by laws of the State
of California for such persons and waives and covenants not to assert or plead any objection which they might otherwise have to
such jurisdiction, venue and such process.

 

    	 	11	 

     

    

 

10.7
Entire Agreement; Amendment. This Agreement, together with the Schedules hereto, and each additional document, instrument
or other agreement to be executed and delivered pursuant hereto constitute all of the agreements of the parties with respect to,
and supersede all prior agreements and understandings relating to the subject matter of, this Agreement or the transactions contemplated
by this Agreement. This Agreement may not be modified or amended except by a written instrument specifically referring to this
Agreement signed by the parties hereto.

 

10.8
Waiver. No waiver by one party of the other party’s obligations, or of any breach or default hereunder by any other
party, shall be valid or effective, unless such waiver is set forth in writing and is signed by the party giving such waiver;
and no such waiver shall be deemed a waiver of any subsequent breach or default of the same or similar nature or any other breach
or default by such other party.

 

10.9
Notices. Any consent, notice or report required or permitted to be given or made under this Agreement by a party to the
other party shall be in writing, delivered by any lawful means to such other party at its address indicated below, or to such
other address as the addressee shall have last furnished in writing to the addressor and (except as otherwise provided in this
Agreement) shall be effective upon receipt by the addressee.

 

	 	If
    to Imprimis:	 	Imprimis
    Pharmaceuticals, Inc.
	 		 	12264
    El Camino Real, Suite 350 
	 		 	San
    Diego, California 92130 
	 		 	Attention:
    Chief Executive Officer 
	 	 	 	 
	 	If
    to Melt:	 	Melt
    Pharmaceuticals, Inc.
	 		 	12264
    El Camino Real, Suite 350 
	 		 	San
    Diego, California 92130 
	 		 	Attention:
    Executive Director 

 

10.10
Counterparts. This Agreement may be executed in separate counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument.

 

***SIGNATURE
PAGE FOLLOWS***

 

    	 	12	 

     

    

 

SIGNATURE
PAGE

 

IN
WITNESS WHEREOF, each party has caused a duly authorized representative to execute and deliver this Asset Purchase Agreement as
of the date below.

 

	IMPRIMIS	 	MELT
	 	 	 
	Imprimis
    Pharmaceuticals, Inc.	 	Melt
    Pharmaceuticals, Inc.
	 	 	 
	 	/s/ Mark L. Baum	 	 	/s/ Andrew R. Boll
	By:	 Mark L. Baum	 	By:	Andrew R. Boll
	Its:	Chief Executive Officer	 	Its:	Executive Director
	 	 	 	 	 
	Date:	12/11/2018	 	Date:	12/11/2018

 

[Signature
Page to Asset Purchase Agreement]

 

    	 	 	 

     

    

 

SCHEDULE
A

 

Assigned
Patent Rights

 

	TITLE	 	INVENTOR(s)	 	COUNTRY	 	STATUS	 	APPLICATION
    #	 	PATENT
    #	 	DATE
    FILED
	PHARMACEUTICAL COMPOSITIONS
    FOR ANESTHESIOLOGICAL APPLICATIONS	 	John Berdahl 
William
    Wiley 
Dennis Saadeh	 	U.S.	 	Issued	 	15/184,768	 	9,918,993	 	June 16, 2016
	PHARMACEUTICAL COMPOSITIONS
    FOR ANESTHESIOLOGICAL APPLICATIONS	 	John Berdahl 
William
    Wiley 
Dennis Saadeh	 	U.S.	 	Expired	 	62/182,130	 	N/A	 	June 19, 2015
	Pharmaceutical
    compositions for anesthesiological applications	 	John Berdahl 
William
    Wiley 
Dennis Saadeh	 	PCT	 	Pending	 	PCT/US16/37893	 	N/A	 	June 16, 2016
	Pharmaceutical
    compositions for anesthesiological applications	 	John Berdahl 
William
    Wiley 
Dennis Saadeh	 	U.S.	 	Pending	 	15/903,529	 	N/A	 	February 23, 2018
	Pharmaceutical
    compositions for anesthesiological applications	 	John Berdahl 
William
    Wiley 
Dennis Saadeh	 	U.S.	 	Pending	 	15/903,615	 	N/A	 	February 23, 2018
	Pharmaceutical
    compositions for anesthesiological applications	 	John Berdahl 
William
    Wiley 
Dennis Saadeh	 	U.S.	 	Pending	 	15/995,875	 	N/A	 	June 1, 2018
	Pharmaceutical
    compositions for anesthesiological applications	 	John Berdahl
    
William Wiley 
Dennis Saadeh	 	AU	 	Pending	 	AU2016280161	 	 	N/A	 	June 16,
    2016
	Pharmaceutical
    compositions for anesthesiological applications	 	John Berdahl 
William
    Wiley 
Dennis Saadeh	 	CA	 	Pending	 	CA2989319	 	 	N/A	 	December 12, 2017
	Pharmaceutical
    compositions for anesthesiological applications	 	John Berdahl 
William
    Wiley 
Dennis Saadeh	 	EP	 	Pending	 	EP 16812447.7	 	 	N/A	 	January 11, 2018
	Pharmaceutical
    compositions for anesthesiological applications	 	John Berdahl 
William
    Wiley 
Dennis Saadeh	 	KR	 	Pending	 	KR 10-2018-7000815	 	 	N/A	 	January 10, 2018
	Pharmaceutical
    compositions for anesthesiological applications	 	John Berdahl 
William
    Wiley 
Dennis Saadeh	 	JP	 	Pending	 	JP 2017-566010	 	 	N/A	 	December 19, 2017Exhibit

Exhibit 10.1

MANAGEMENT CASH INCENTIVE GOVERNING PLAN
Effective January 1, 2019

1. Purpose of the Plan
The purpose of the Management Cash Incentive Governing Plan (the “Plan”) is to provide the foundation for the Management Cash Incentive Plan, and all other cash incentive plans.  The Plan is designed to  (i) motivate, recognize, and reward designated Plan Participants  for their contributions to the sustained performance and success of Northfield Bancorp, Inc. and its subsidiaries (the “Company” or the “Bank”) and (ii) link executive compensation to the attainment of specific corporate performance.  The Plan serves as a critical component of a competitive total compensation package that enables the Company to attract and retain talent needed to drive the Company’s future success.    
2. Definitions
Affiliate means Northfield Bank, or any other entity controlled by the Company.
Award means a cash payment made to a Participant pursuant to the terms of this Plan.
Base Salary means, as to a Performance Period, a Participant’s actual salary rate in effect as of the last business day of the Performance Period.  Such salary shall be before (i) deductions for taxes and benefits, and (ii) deferrals of compensation pursuant to Company- or Affiliate-sponsored plans.
Board means the Board of Directors of the Company.
Code means the Internal Revenue Code of 1986, as amended.  Reference to a specific section of the Code shall include such section, any valid regulation promulgated there under, and any comparable provision of any future legislation or regulation amending, supplementing or superseding, such section or regulation.
Committee means the Compensation Committee of the Company’s Board of Directors, or any other committee appointed by the Board pursuant to Section 3.1 of the Plan.
Company means Northfield Bancorp, Inc, a Delaware corporation.
Determination Date means, as to a Performance Period, the date upon which the Committee sets forth in writing the Performance Measures attributable to a Participant or the Participants.  The Determination Date shall be no later than the earlier of (i) 90 days after the commencement of the Performance Period or (ii) the date on which 25 percent of the Performance Period has elapsed, provided, in either case, that the outcome is substantially uncertain at the time the Committee actually establishes the Performance Measures.1 
Participant means, as to any Performance Period, an officer of the Company or an Affiliate at the level of senior vice president or above, or one who has been selected by the Committee for participation in the Plan for such Performance Period.
Performance Measure means the performance criteria set forth in Section 5.4 of the Plan.

_______________________________________________________________________________________________________________________________________________________________________________ 
1 The “Determination Date” concept is set forth under the Code Section 162(m) regulations.  Accordingly, since the qualified performance-based compensation exemption has been eliminated, technically, this concept is no longer required.  However, we believe this may be a valuable concept to preserve, i.e., actually setting the performance measures before the outcome is likely to be quantified.  

Performance Period means a period of not less than 12 months and not greater than 36 months that is designated by the Committee for the purposes specified herein.  Subject to Code Section 162(m), the Committee may designate one or more Performance Periods which may or may not run concurrently.
Termination of Employment means the time when the employee-employer relationship between the Participant and the Company and its Affiliates is terminated for any reason, including, but not limited to, a termination by resignation, discharge, death, permanent disability, or retirement, but excluding any such termination where there is a simultaneous reemployment by either the Company or an Affiliate.
3. Administration of the Plan
3.1 The Plan shall be administered by the Compensation Committee (the “Committee”)  of the Company who are “independent directors” as defined by the stock exchange rules to which the Company is subject..  
3.2 Subject to the provisions of the Plan, the Committee shall have exclusive authority to select the Plan Participants for a Performance Period, determine the relative percentages of the Award based upon Company performance and individual performance, and determine the Award levels and the performance thresholds that must be achieved prior to payment of Awards.  For each Performance Period, all such actions shall be taken by the Determination Date.  Notwithstanding anything to the contrary herein, all Awards made by the Committee and any performance criteria established by the Committee with respect to an Award, shall be subject to the ratification of the Board of Directors.
3.3 The Committee shall have all discretion and authority necessary or appropriate to administer the Plan, including, but not limited to, the power to interpret the Plan, to prescribe, amend, and rescind rules and regulations relating to it and to make all other determinations necessary or advisable in the administration of the Plan.  Such determination shall be final and binding upon all persons having an interest in the Plan.
3.4 A majority of the Committee shall constitute a quorum, and the acts of a majority of the members present at a meeting at which a quorum is present, or any action taken without a meeting by a writing executed by a majority of the Committee, shall constitute the act of the Committee.
3.5 All expenses and liabilities incurred by the Committee in the administration of the Plan shall be borne by the Company.  The Committee may employ attorneys, consultants, accountants, or other persons, and the Committee, the Company and its officers and directors shall be entitled to rely upon the advice, opinion, or valuations of any such persons, in accordance with the Committee’s charter approved by the Board of Directors.  No member of the Committee shall be personally liable for, and all members of the Committee shall be fully protected by the Company in respect of, any action, determination, or interpretation taken or made with respect to the Plan, unless such action, determination, or interpretation constitutes criminal misconduct, willful negligence, or demonstrates bad faith.
4. Eligibility and Participation
The Plan is designed for the benefit of those senior officers, and selected team members of the Company and its Affiliates whose responsibilities and performance significantly influence Company results.  Plan Participants shall be selected by the Committee for each Performance Period prior to or on the Determination Date for such Performance Period.  Participation in the Plan is on a Performance Period basis only and in the sole discretion of the Committee.  No Participant with respect to a specific Performance Period shall be entitled to participate in the Plan in a subsequent Performance Period unless selected as a Participant for such Performance Period by the Committee.
5. Determination of Awards
5.1 Prior to or on the Determination Date, the Committee, in its sole discretion, shall assign each Participant a target Award and prescribe all other factors to be used for determining the amount of the Awards to be paid to Participants pursuant to the Plan for a Performance Period.  The Committee shall also prescribe the percentage of the target Award for each Participant that will be determined based upon 

Company Performance Measures and the percentage that will be determined based upon individual performance factors.  Target Awards shall be expressed as a percentage of Base Salary.  Notwithstanding any other provision of the Plan, the maximum Award payable pursuant to the Plan to a Participant for any Performance Period shall be 150% of the Target Award.
5.2 The Committee shall prescribe what portion of the target Award will be determined based upon each type of Performance Measure to be used for a Performance Period, and the level of achievement of each such goal for the Performance Period that must be reached to earn the portion of the target Award related to such goal.  The Committee may also prescribe levels of achievement that will result in an Award higher or lower than the target Award and set minimum achievement thresholds below which no Award based on the particular performance goal will be paid.
5.3 Actual corporate performance will determine the amount of the portion of the Award related to Company performance for each individual Participant that has been earned based on the extent to which the pre-determined thresholds are achieved or exceeded by the Company.  All calculations related to the Performance Measures listed in Sections 5.4 shall be made in accordance with generally accepted accounting principles and may exclude any significant non-recurring items that are specified by the Committee.  Specifically, (i) Performance Measures based upon cash earnings or cash returns may refer to, or be calculated based upon, net income adjusted to exclude non-cash charges for goodwill amortization and non-cash amortization expenses relating to employee stock ownership plans and restricted stock plans and (if applicable) related tax benefits and (ii) Performance Measures based upon cash operating expenses shall refer to operating expenses, calculated in accordance with GAAP, adjusted to eliminate non-cash charges for goodwill amortization and non-cash amortization expenses relating to employee stock ownership plans and restricted stock plans and (if applicable) related tax benefits.
5.4 The Committee, in its sole discretion, may select the Performance Measures for any Performance Period from among the following:
i.Book value or tangible book value per share
ii.basic earnings per share;
iii.basic cash earnings per share;
iv.diluted earnings per share;
v.diluted cash earnings per share;
vi.net income or net income before taxes;
vii.cash earnings;
viii.net interest income;
ix.non-interest income;
x.non-interest expense to average assets ratio;
xi.efficiency ratio;
xii.cash efficiency ratio;
xiii.return on average assets;
xiv.cash return on average assets;
xv.return on average stockholders' equity;
xvi.cash return on average stockholders' equity;
xvii.return on average tangible stockholders' equity;
xviii.cash return on average tangible stockholders' equity;
xix.core earnings;

xx.operating income;
xxi.operating efficiency ratio;
xxii.net interest rate margin or net interest rate spread;
xxiii.growth in assets, loans, or deposits;
xxiv.loan production volume;
xxv.non-performing loans;
xxvi.cash flow;
xxvii.strategic business objectives, consisting of one or more objectives based upon meeting specified cost targets, business expansion goals, and goals relating to acquisitions or divestitures, or goals relating to capital raising and capital management; or
xxviii.any combination of the foregoing.
5.5 The Committee shall prescribe the portion of the target Award that will be determined based upon each type of individual performance goal to be used for a Performance Period, and the levels of achievement of each such goal for the Performance Period that must be reached to earn the portion of the target Award related to such goal.  The Committee may also prescribe levels of achievement that will result in an Award higher or lower than the target Award and set minimum achievement thresholds below which no Award based on the particular performance goal will be earned.  The portion of the Award related to individual performance goals shall be based upon satisfactory achievement of the individual performance goals established by the Committee.  The Committee shall take into consideration the advice of the President and Chief Executive Officer of the Company for this purpose, but the Committee shall make the final determination.
5.6 Except as provided in this Section 5.6, Performance Measures established for a specified Performance Period shall not thereafter be subject to revision or alteration.  In the event the Committee determines that a revision or alteration of the target Awards or Performance Measures for a specified Performance Period is appropriate, the Committee shall reestablish such target Awards or Performance Measures to maintain as closely as possible the previously established expected level of overall performance, taken as a whole, as is practicable. In connection with a possible revision or alteration of Performance Measures, the Committee may consider factors including, but not limited to, the occurrence of a business combination involving the Company, the declaration and distribution of stock dividends or stock splits, mergers, consolidation or reorganizations, acquisitions or dispositions of a material business units, or infrequently occurring or extraordinary gains or losses.
5.7 The Committee may, in its sole discretion, adjust the amount of an Award for any or all Participants if it determines that circumstances (including, but not limited to, the subjective appraisal of the Participant’s performance for the Performance Period) warrant.  
5.8 Any provision of this Plan to the contrary notwithstanding, in the event that an individual becomes employed by the Company or an Affiliate after the beginning of the Performance Period and the Committee, in its sole discretion, selects such individual for participation in the Plan for such initial Performance Period of employment, the Committee may designate a short performance period (instead of the Performance Period) for purposes of this Plan for such Participant that ends on the last day of such Performance Period but begins on a date that is later than the first day of such Performance Period.  In such event, the Committee shall establish levels of achievement for the short performance period for those performance factors selected by the Committee for such Participant under the preceding provisions of this Article 5.  References in the Plan to the “Performance Period” with respect to any such Participant shall refer to the short performance period established by the Committee pursuant to this Section 5.6.   

6. Payments To Participants and Reimbursements to the Company
Prior to the payment of any Awards, the Committee shall certify in writing the level of achievement for each Company performance goal for the Performance Period and the level of achievement by each Participant with respect to any individual performance goals applicable to such Participant’s award and determine the amount of the Award, if any, payable to each Participant.  Payment of Awards shall be made in cash as soon as administratively practicable following the Committee’s certification.  Participants shall be entitled to elect, prior to a date specified by the Compensation Committee, to defer receipt of a cash payment in accordance with the terms of any Company deferred compensation plan in effect at the time and applicable to such cash payment.  Notwithstanding any contrary provision of the Plan, (a) if a Participant experiences a Termination of Employment prior to the end of a Performance Period and the established performance goals have been satisfied fully or partially, the Committee, in its sole discretion, may reduce or eliminate the Award to be paid to such Participant for such Performance Period pursuant to this Plan and the Award, if any, paid to such a Participant will be paid at the same time as applicable to all Participants, and (b) no provision of the Plan shall be construed to create a trust or to establish or evidence any Participant’s claim of any right other than as an unsecured general creditor with respect to any payment to which he or she may be entitled. The Company shall withhold all applicable taxes required by law from any payment, including any federal, FICA, state, and local taxes.
Participants of this Plan agree that the Company has the right to recoup or “clawback” awards paid under this Plan if the Compensation Committee concludes that such awards were based on information that was later found to be materially incorrect, including awards that were determined, in whole or in part, on financial statement information that is subsequently restated.  This includes any error that is material to previously-issued financial statements that results in notification that they cannot be relied upon.   Additionally, if the Committee determines, upon review of the facts and circumstances, that an executive officer conducted his or herself in violation of the terms of the executive officer’s Employment Agreement, the Committee may determine that incentive compensation awards may or may not be revoked.  Participants of the Plan agree that such recoupment would be made in accordance with prevailing laws and regulations.  The Company also has the right to revise its clawback requirements, or policies subject to this Plan, if changes in laws and regulations require (or permit) the Company to do so.
7. Employment Rights
Nothing in the Plan shall confer upon any Participant the right to continue in the employ of the Company or its Affiliates or shall interfere with or restrict in any way the rights of the Participant’s employer to discharge or change the terms of employment of any Participant at any time for any reason whatsoever, with or without cause.
8. Effect Upon Other Plans
The adoption of the Plan shall not affect any other equity or other compensation or incentive plan in effect for the Company or any Affiliate, and the Plan shall not preclude the Board from establishing any other forms of incentive compensation for employees of the Company or its Affiliates.
9. Governing Law
The Plan shall be construed, administered, and enforced according to the laws of the State of New Jersey, without giving effect to the conflict of laws principles thereof, except to the extent that such laws are preempted by federal law.
10. Notices 
Any communication required or permitted to be given under the Plan, including any notice, direction, designation, comment, instruction, objection, or waiver, shall be in writing and shall be deemed to have been given at such time as it is delivered personally or five (5) days after mailing if mailed, postage prepaid, by registered or certified mail, return receipt requested, addressed to the Committee, at 

the Company’s principal executive offices, and to a Participant, to the Participant’s address as shown in the Company’s personnel records.
11. Successors and Assigns
The provisions of the Plan shall inure to the benefit of and be binding upon, the Participants and their respective legal representatives and testate or intestate distributes, and the Company, its Affiliates, and their respective successors and assigns, including any successor by merger or consolidation or a statutory receiver or any other person or firm or corporation to which all or substantially all of the assets and business of the Company may be sold or otherwise transferred. 
12. Amendment, Suspension, or Termination of the Plan
The Board, in its sole discretion, may alter, amend, or terminate the Plan, or any part thereof, at any time and for any reason.  
13. Severability
If any provision of the Plan is or becomes or is deemed to be invalid, illegal, or unenforceable in any jurisdiction, such provision shall be construed or deemed amended to conform to applicable laws, or if it cannot be so construed or deemed amended without, in the determination of the Committee, materially altering the purpose or intent of the Plan, such provision shall be stricken as to such jurisdiction, and the remainder of the Plan shall remain in full force and effect.
15. Effective Date
The Plan shall be effective upon adoption by the Board of Directors of the Company.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}]]